Beijing Anshi Biotechnology

Beijing Anshi Biotechnology is a clinical-stage biotechnology company specializing in the development of mRNA-based vaccines and therapeutics. Founded in 2021 and headquartered in Beijing, the company leverages a proprietary mRNA-LNP (lipid nanoparticle) delivery platform to address infectious diseases and other therapeutic areas. Its lead candidate, AS01, is an mRNA vaccine for shingles (herpes zoster) currently in Phase 1/2 clinical trials. The company's pipeline also includes programs for respiratory syncytial virus (RSV), influenza, and various other viral pathogens. Anshi Biotechnology has secured significant backing from prominent investors such as Hillhouse Investment and Qiming Venture Partners. The firm aims to establish a full-suite capability spanning R&D, clinical development, and large-scale manufacturing for mRNA products.